» Articles » PMID: 25076177

Functional Polymers of Gene Delivery for Treatment of Myocardial Infarct

Overview
Specialty Pharmacology
Date 2014 Jul 31
PMID 25076177
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Ischemic heart disease is rapidly growing as the common cause of death in the world. It is a disease that occurs as a result of coronary artery stenosis and is caused by the lack of oxygen within cardiac muscles due to an imbalance between oxygen supply and demand. The conventional medical therapy is focused on the use of drug eluting stents, coronary-artery bypass graft surgery and anti-thrombosis. Gene therapy provides great opportunities for treatment of cardiovascular disease. In order for gene therapy to be successful, the development of proper gene delivery systems and hypoxia-regulated gene expression vectors is the most important factors. Several non-viral gene transfer methods have been developed to overcome the safety problems of viral transduction. Some of which include plasmids that regulate gene expression that is controlled by environment specific promoters in the transcriptional or the translational level. This review explores polymeric gene carriers that target the myocardium and hypoxia-inducible vectors, which regulate gene expression in response to hypoxia, and their application in animal myocardial infarction models.

Citing Articles

Nanocarrier-Based Targeted Therapies for Myocardial Infarction.

George T, Hsu C, Meeson A, Lundy D Pharmaceutics. 2022; 14(5).

PMID: 35631516 PMC: 9143269. DOI: 10.3390/pharmaceutics14050930.


Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies.

Meng H, Cheng W, Wang L, Chen S, Teng Y, Lu Z J Cardiovasc Transl Res. 2021; 15(2):317-339.

PMID: 34611844 DOI: 10.1007/s12265-021-10168-y.


VEGF121 Mediates Post-Hypoxia Cardioprotective Effects Via CaSR and Mitochondria-Dependent Protease Pathway.

Zhang Y, Yin W, Yang F, An Y, Zhou W, Yu H Arq Bras Cardiol. 2021; 117(3):476-483.

PMID: 34550233 PMC: 8462959. DOI: 10.36660/abc.20190902.


Can thiol-based redox systems be utilized as parts for synthetic biology applications?.

Pillay C, John N Redox Rep. 2021; 26(1):147-159.

PMID: 34378494 PMC: 8366655. DOI: 10.1080/13510002.2021.1966183.


and evaluation of liposomes modified with polypeptides and red cell membrane as a novel drug delivery system for myocardium targeting.

Liu X, Zhang L, Jiang W, Yang Z, Gan Z, Yu C Drug Deliv. 2020; 27(1):599-606.

PMID: 32308051 PMC: 7191910. DOI: 10.1080/10717544.2020.1754525.


References
1.
Christensen L, Chang C, Yockman J, Conners R, Jackson H, Zhong Z . Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery. J Control Release. 2007; 118(2):254-61. PMC: 2563956. DOI: 10.1016/j.jconrel.2006.12.018. View

2.
Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M . High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45(9):1406-12. DOI: 10.1016/j.jacc.2005.01.043. View

3.
Losordo D, Vale P, Hendel R, Milliken C, Fortuin F, Cummings N . Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002; 105(17):2012-8. DOI: 10.1161/01.cir.0000015982.70785.b7. View

4.
Won Y, Lee M, Kim H, Nam K, Bull D, Kim S . Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis. Mol Pharm. 2013; 10(10):3676-83. PMC: 3818911. DOI: 10.1021/mp400178m. View

5.
Nam H, Kim J, Kim S, Yockman J, Kim S, Bull D . Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery. Biomaterials. 2011; 32(22):5213-22. PMC: 3128881. DOI: 10.1016/j.biomaterials.2011.03.058. View